Search

Displaying results 291 - 300 of 10000 in total
  1. Drug

    Glucosamine

    go.drugbank.com/drugs/DB01296
    Approved

    Osteoarthritis (OA) is a progressive and degenerative joint disease marked by loss of cartilage, bone changes, and synovial membrane inflammation. Treatment with chondroprotective drugs, such as glucosamine sulfate may offer additional b...

    Mixtures: flexijoint 3-in-1 Joint Care Powder, OSTEOACTIV 3-in-1 Joint Formula PowderProducts: OSTEOACTIV 1000mg Powder, GLUCOSAMINA SOLFATO EG
  2. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. … Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing

    Products: CYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML, Cyramza 100mg/10ml concentrate for solution for infusion
  3. Drug

    Febuxostat

    go.drugbank.com/drugs/DB04854
    ApprovedInvestigational

    The manufacturer and the FDA advise health professionals to limit the use of febuxostat to second-line therapy in patients who have inadequate response or intolerance to allopurinol, and to avoid the use … [A230548] In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout who have an inadequate response or intolerance to [allopurinol

    Products: FEBUXOSTAT EG, ADENURIC 120MG
  4. Drug

    Amitriptyline

    go.drugbank.com/drugs/DB00321
    ApprovedInvestigational

    ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. … [A259342] Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.[A174661]

    Synonyms: 10,11-dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-Δ5,γ-propylamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamineProducts: AMITRIPTILINA EG, AMITRIPTYLIN SDZ 100MG RET
  5. Drug

    Flubendazole

    go.drugbank.com/drugs/DB08974
    ApprovedInvestigationalWithdrawn

    Flubendazole is an anthelmintic that is used to treat worm infection in humans. It is available OTC in Europe.

    Products: HELMIN EX SUSPENSION 100MG/5ML, FLUBENDAZOL 300MG
  6. Drug

    Spironolactone

    go.drugbank.com/drugs/DB00421
    ApprovedInvestigational

    [A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]

    Mixtures: SPIRO D TABLINEN 100MGProducts: DIUXOTON® 100MG, ESPIRONOLACTONA 100MG
  7. Drug

    Nizatidine

    go.drugbank.com/drugs/DB00585
    Approved

    A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.

    Synonyms: N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamineProducts: ICIN ENJ. AMPUL, 5 ADET, Dom-nizatidine 150mg Capsules
  8. Drug

    Acetylcysteine

    go.drugbank.com/drugs/DB06151
    ApprovedInvestigational

    [A228158,A228163,A228168] Acetylcysteine was granted FDA approval on 14 September 1963.[L31488] … Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of [acetaminophen] overdose.

    Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSIONCategories: Compounds used in a research, industrial, or household setting
  9. Drug

    Bicalutamide

    go.drugbank.com/drugs/DB01128
    ApprovedInvestigational

    Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers.

    Products: BICALUTAMIDE EG, BICALUTAMIDE EG STADA
  10. Drug

    Desvenlafaxine

    go.drugbank.com/drugs/DB06700
    ApprovedInvestigational

    [L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. … [A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).

    Products: Pristiq Extended-Release Tablet 100mg, FAPRIS® 100MG TABLETAS DE LIBERACION PROLONGADA